-Reuters
Akari Therapeutics Presents Poster On Progress In Pre-Clinical Development Of Long-Acting PAS-Nomacopan As A Potential Treatment For Geographic Atrophy At The 4th Annual Dry AMD Therapeutic Development Conference
Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the presentation of progress in the development of